Invitation to Roche’s virtual Neuroscience Update IR Event Montag, 02. Oktober 2023 - 10:21

We are pleased to invite investors and analysts to participate in our virtual event on Monday, 30 October 2023, highlighting Roche's Neuroscience portfolio, including the latest data presented at ECTRIMS 2023 (Ocrevus, fenebrutinib) and CTAD 2023 (trontinemab, gamma-secretase modulator).

17:00 – 18:15 CET / 16:00 - 17:15 GMT

12:00 – 1:15 pm EDT / 9:00 – 10:15 am PDT

The webinar will start with presentations, followed by a Q&A session (live access to the speakers). The slides will be available for download at 16:00 CET on the day of the event. > click here

Access to virtual event (pre-registration required)

Please pre-register for our webinar here*.

Should you be unable to register for the webinar due to your company IT policy, please send an e-mail to investor.relations@roche.com.

A replay of the webcast will be available via > ir.roche.com

*privacy notice

Best regards,

Bruno Eschli
Head of Investor Relations

Roche Investor Relations

Dr. Bruno Eschli

Phone: +41 61 68-75284

e-mail: bruno.eschli@roche.com

Dr. Sabine Borngräber

Phone: +41 61 68-88027

e-mail: sabine.borngraeber@roche.com

Dr. Birgit Masjost

Phone: +41 61 68-84814

e-mail: birgit.masjost@roche.com

Dr. Gerard Tobin

Phone: +41 61 68-72942

e-mail: gerard.tobin@roche.com

Investor Relations North America

Loren Kalm

Phone: +1 650 225 3217

e-mail: kalm.loren@gene.com